Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
Abstract
Background/objective There are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6 months. We aim to assess weight loss, metabolic, and cardiovascular outcomes of 12 months of semaglutide.Subject/methods We conducted a multicentered retrospective cohort study on semaglutide use. We included patients with a body-mass index (BMI) ≥ 27 kg/m 2 who were prescribed weekly semaglutide subcutaneous injections. We excluded patients with bariatric surgeries, taking other anti-obesity medications, and with active malignancy or pregnancy. A total of 1023 patients had semaglutide prescription for obesity.Intervention/methods We assessed weight loss outcomes of subcutaneous semaglutide for 12 months. The primary endpoint was total body weight loss percentage (TBWL%) at 12 months. Secondary endpoints included proportion of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss, and improvements in metabolic, cardiovascular, and comorbidities after 12 months of follow-up.Results We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m 2) in the analysis. Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p < 0.001 from baseline). Patients without T2DM achieved a TBWL of 16.9 (6.9)% compared to 9.9 (8.4)% in patients without T2DM at 12 months on the higher doses of semaglutide (p < 0.001 from baseline). In this cohort, 81% achieved ≥5%, 64% achieved ≥10%, 41% achieved ≥15%, and 22% achieved ≥20% TBWL at 12 months. Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.Conclusions Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed weight reduction in clinical practice overall tends to be lower than in randomized controlled trials; however, outcomes approach those seen in trials when focusing on highly adherent patients.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [58]
In the citing paper
“Importantly, the weight‐loss effectiveness of GLP‐1RA was similar to what has been observed in trials when focusing on the subgroup of adherent patients who consistently took their prescribed GLP‐1RA, for example, at 12 months follow‐up, 50 , 53 , 55 , 56 , 57 , 58 , 61 whereas studies reporting results in an ‘as‐started’ approach found considerably lower effectiveness. 52 , 59 , 63 , 66”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [58]
In the citing paper
“Semaglutide and tirzepatide initiators appeared to achieve the greatest weight loss in real life, and weight loss effects were weaker for patients with T2D than for obese people without diabetes, 52 , 58 , 65 , 67 which was also observed in trials. 18 , 75”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [58]
In the citing paper
“loss effects were weaker for patients with T2D than for obese people without diabetes, 52 , 58 , 65 , 67 which was also observed in trials. 18 , 75”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [58]
In the citing paper
“Semaglutide and tirzepatide initiators appeared to achieve the greatest weight loss in real life, and weight loss effects were weaker for patients with T2D than for obese people without diabetes, 52 , 58 , 65 , 67 which was also observed in trials. 18 , 75”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [58]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 16×
“Furthermore, semaglutide has also shown remarkable metabolic and comorbidities improvement in RCTs [3].”
InfluentialDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 2×
“However, after adjusting for T2DM status in a multiple logistic regression analysis, there was no difference in weight loss outcomes between patients with and without dietitian visits ( p = 0.15).”
InfluentialWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
Söderberg, C., Stål, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., & Hultcrantz, R. (2010) · Hepatology · doi:10.1002/hep.23314 · Cited by 754
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31982 · Cited by 238
Self-citationSørensen, T. I. A., Martínez, A. R., & Jørgensen, T. S. H. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_581 · Cited by 143
Research works printed but not linked: 1
- Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279038/. 2015.
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
“In fact, multiple studies have been demonstrating the survival benefit of these medications [33,34].”
BackgroundSelf-citationSzekeres, Z., Nagy, A., Jahner, K., & Szabados, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158214 · Cited by 77
“Furthermore, patients diagnosed with non-alcoholic fatty liver disease had a significant decrease in aspartate transferase and alanine transferase as well [18].”
BackgroundIncretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Conversely, the first multicenter real-world cohort study reported an average 13.4% loss (97), comparable to the STEP 1 clinical trial data (79), implying a variable response to semaglutide in different trial and real-world settings.”
Influential
Metadata
- Authors
- Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feres, F., Hurtado, M. D., & Acosta, A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Acosta, Andres
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2024-02-01
- Volume
- 48
- Issue
- 5
- Pages
- 662-667
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4391445680
- Cited by
- 35
- References
- 16
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 9
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114460)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, weight loss, obesity, type 2 diabetes, cardiovascular risk, metabolic outcomes, lipid profile, blood pressure, liver function tests, anti-obesity drugs, GLP-1 receptor agonists
- MeSH terms
- Heart Disease Risk Factors, Semaglutide, Adult, Cardiovascular Diseases, Glucagon-Like Peptides, Female, Humans, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. https://app.cochat.ai/papers/10.1038/s41366-023-01456-5
- The paper
- Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feres, F., Hurtado, M. D., & Acosta, A. (2024). Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. International Journal of Obesity. https://doi.org/10.1038/s41366-023-01456-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.